2024 Aug-雅法全球生物医药交易月报 YAFO Global Biopharma Transactions Report

2024-09-02

1. Executive Summary of the Month

2024年8月，全球医药市场共签署了47项资产授权和合作协议。其中，中国医药市场达成24项交易，包括11项出海交易、3项引进交易，和10项引进交易。

本月中国市场最引人注目的出海交易是同润生物向MSD授权一款Phase ½期资产CN201，首付款7亿美元，总价值13亿美元。值得关注的引进交易是华东医药引进Imbiologics公司资产IMB-101和IMB-102，首付600万美元，总金额3.16亿美元。值得关注的国内交易是艾力斯引进加科思JAB-3312和glecirasib两款资产，首付2100万美元，总金额1.18亿美元。

国际市场上，8月份共签署了23项资产授权和合作协议。最大的一笔交易是MSD与Daiichi Sankyo就前者的HPN823资产达成的合作交易，首付款1.70亿美元。

In August, a total of 47 licensing and cooperation deals were signed globally. Within the China Biotech Industry, 24 deals were signed, including 11 out-licensing deals, 3 in-licensing deals, and 10 domestic deals.

Notably, the top out-licensing deal of the month was between Curon Biopharmaceutical and Merck & Co., involving the Phase I/II asset CN201. This high-profile agreement is valued at $1.3 billion, with an upfront payment of $700 million. The most prominent in-licensing deal was the $316 million deal between Imbiologics and Huadong Medicine for IMB-101 and IMB-102, which included an upfront payment of $6 million. The standout domestic deal was between Jacobio Pharmaceuticals and Allist Pharmaceuticals for the licensing of JAB-3312 and glecirasib, valued at $118 million with an upfront payment of $21 million.

On a global scale, 23 licensing and cooperation deals were concluded. Among these, the agreement between Merck & Co. and Daiichi Sankyo for HPN823 was notable, featuring an upfront payment of $170 million.

2. Licensing Deals

2a. Out-Licensing Deals

2b. In-Licensing Deals

2c. Domestic Licensing Deals

3. 2019-2023 China Innovative Drug Licensing Transactions

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit http://www.yafocapital.com

ACCESS CHINA